125 related articles for article (PubMed ID: 38218717)
1. Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients.
Alsultan A; Aldawsari MR; Alturaiq NK; Syed SA; Alsubai A; Kurdee Z; Alsubaie S; Alqahtani S; Abouelkheir M
Pediatr Neonatol; 2024 Jan; ():. PubMed ID: 38218717
[TBL] [Abstract][Full Text] [Related]
2. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
[TBL] [Abstract][Full Text] [Related]
3. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
Gijsen M; Elkayal O; Annaert P; Van Daele R; Meersseman P; Debaveye Y; Wauters J; Dreesen E; Spriet I
Infect Drug Resist; 2022; 15():53-62. PubMed ID: 35035223
[TBL] [Abstract][Full Text] [Related]
4. Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
He X; Liu X; Gong X; Wang L; Chen F
Curr Drug Metab; 2023; 24(1):5-15. PubMed ID: 36974414
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia.
Alsultan A; Dasuqi SA; Aljamaan F; Omran RA; Syed SA; AlJaloud T; AlAhmadi A; Alqahtani S; Hamad MA
Saudi Pharm J; 2021 Nov; 29(11):1272-1277. PubMed ID: 34819789
[TBL] [Abstract][Full Text] [Related]
6. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
[TBL] [Abstract][Full Text] [Related]
7. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients.
Luque S; Benítez-Cano A; Larrañaga L; Sorlí L; Navarrete ME; Campillo N; Carazo J; Ramos I; Adalia R; Grau S
Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34204943
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.
Gijsen M; Dreesen E; Van Daele R; Annaert P; Debaveye Y; Wauters J; Spriet I
Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34064676
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
[TBL] [Abstract][Full Text] [Related]
13. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
[TBL] [Abstract][Full Text] [Related]
14. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
15. Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study.
Helset E; Cheng V; Sporsem H; Thorstensen C; Nordøy I; Gammelsrud KW; Hanssen G; Ponzi E; Lipman J; von der Lippe E
Acta Anaesthesiol Scand; 2024 Apr; 68(4):502-511. PubMed ID: 38286568
[TBL] [Abstract][Full Text] [Related]
16. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.
Cies JJ; Moore WS; Enache A; Chopra A
J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823
[TBL] [Abstract][Full Text] [Related]
18. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
19. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Target Attainment of Ceftazidime in Adult Patients on General Wards with Different Degrees of Renal Function: A Prospective Observational Bicenter Cohort Study.
Zieck SE; de Vroom SL; Mulder FP; van Twillert G; Mathôt RAA; Geerlings SE; van Hest RM
Antibiotics (Basel); 2023 Feb; 12(3):. PubMed ID: 36978336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
